



RECEIVED

OCT 22 2001

TECH CENTER PATENT

ATTORNEY DOCKET NO. 502117005002

Certificate of Mailing: Date of Deposit: 10/15/01

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Mary Jane DiPalma
Printed Name of Person Mailing Correspondence

Mary Jane DiPalma
Signature of Person Mailing Correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Judes Poirier

Art Unit: 1653

Serial No.: 09/342,993

Examiner: Tu, S.

Filed: June 29, 1999

Title: APOLIPOPROTEIN E POLYMORPHISM AND TREATMENT OF ALZHEIMER'S DISEASE

Commissioner For Patents
Washington, DC 20231

PETITION TO CORRECT OFFICIAL FILING RECEIPT

Applicant requests that the attached filing receipt be corrected to insert after

"Applicant(s) Judes Poirier, Boisbriand, Canada;" the following:

Domestic Priority data as claimed by applicant

This application is a continuation of and claims priority from United States patent publication 08/727,637, filed October 16, 1996 which is the U.S.


National Phase of CA95/00240 filed April, 1995, which is the PCT International of 9408465.4 (Great Britain) filed April 27, 1994.

Attached is a copy of the incorrect filing receipt and the Application Transmittal containing the correct priority information.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: October 15, 2001



Kristina Bieker Brady, Ph.D.
Reg. No. 39,109


Clark & Elbing LLP
176 Federal Street
Boston, MA 02110-2214
Telephone: 617-428-0200
Facsimile: 617-428-7045

50211.005002 Petition to correct filing receipt.doc



21559


PATENT TRADEMARK OFFICE



UNITED STATES PATENT AND TRADEMARK OFFICE

 RECEIVED
 OCT 22 2001
 TECH CENTER 1600/290
 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/342,993	06/29/1999	1614	724	08523/005002 50211	12	13	4

 KRISTINA BIEKER BRADY
 CLARK AND ELBING LLP
 176 FEDERAL STREET
 BOSTON, MA 02110

 CONFIRMATION NO. 7392
 CORRECTED FILING RECEIPT


OC000000005903147

Date Mailed: 03/26/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

JUDES POIRIER, BOISBRIAND, CANADA;

Continuing Data as Claimed by Applicant

This application is a continuation of U.S. SN. 08/727,637, filed 10/16/96
 Foreign Applications which is a 371 of CA/95/00240, filed 4/1995

UNITED KINGDOM 9408465.4 04/27/1994

If Required, Foreign Filing License Granted 08/04/1999

Projected Publication Date: 07/05/2001

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

APOLIPOPROTEIN E POLYMORPHISM AND TREATMENT OF ALZHEIMER'S DISEASE

Preliminary Class

435

Data entry by : RIMANDO, EMELITA

Team : OIPE

Date: 03/26/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED


No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:


- o The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- o The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- o The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- o The docket number allows a maximum of 25 characters.
- o If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- o The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

Certificate of Mailing	
Date of Deposit <u>June 29, 1999</u>	Label Number: <u>EJ553549138US</u>
<p>I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.</p>	
<u>Sandra E. Marxen</u> Printed name of person mailing correspondence	 Signature of person mailing correspondence

UTILITY PATENT APPLICATION TRANSMITTAL UNDER 37 CFR §1.53(b)	
Attorney Docket Number	08523/005002
Applicant	Judes Poirier
Title	APOLIPOPROTEIN E POLYMORPHISM AND TREATMENT OF ALZHEIMER'S DISEASE
PRIORITY INFORMATION:	
<p>This application is a continuation of and claims priority from United States patent application 08/727,637, filed October 16, 1996 which is the U.S. National Phase of CA95/00240 filed April 26, 1995, which is the PCT International of 9408465.4 (Great Britain) filed April 27, 1994.</p>	
APPLICATION ELEMENTS:	
Cover sheet	[1] page
Specification	[28] pages
Claims	[2] pages
Abstract	[1] pages
Drawing	[12] pages
Transmission of Formal Drawings to Official Draftsperson	[2] pages
Petition To Accept Black & White Photographs	[2] page
Combined Declaration and POA, which is: <input type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input checked="" type="checkbox"/> A copy from prior application 08/727,637 and the entire disclosure of the prior application is considered as being part of the disclosure of this new application and is hereby incorporated by reference therein.	[2] pages
Statement Deleting Inventors	[**] pages
Sequence Statement	[**] pages
Sequence Listing on Paper	[**] pages
Sequence Listing on Diskette	[**] pages

Small Entity Statement, which is: <input type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input checked="" type="checkbox"/> A copy from prior application 08/727,637 and such small entity status is still proper and desired.	[2] pages
Preliminary Amendment	[**] pages
IDS	[**] pages
Form PTO 1449	[**] pages
Cited References	[**] pages
Recordation Form Cover Sheet and Assignment	[3] pages
Assignee's Statement	[**] pages
English Translation	[**] pages
Certified Copy of Priority Document	[**] pages
Return Receipt Postcard	1
FILING FEES:	
Basic Filing Fee: \$380	\$380.00
Excess Claims Fee: 13 - 20 x \$9	\$00.00
Excess Independent Claims Fee: 4 - 3 x \$39	\$39.00
Multiple Dependent Claims Fee: \$130	\$130.00
Total Fees:	\$549.00
<input checked="" type="checkbox"/> Enclosed are checks for \$549.00, \$40.00 and \$130.00 to cover the requisite fees. <input type="checkbox"/> Charge [**AMOUNT**] to Deposit Account No. 03-2095 to cover the total fees. <input type="checkbox"/> The filing fee is not being paid at this time. <input checked="" type="checkbox"/> Please apply any other charges, or any credits, to Deposit Account No. 03-2095.	
CORRESPONDENCE ADDRESS:	
Kristina Bieker-Brady Reg. No. 39,109 Clark & Elbing LLP 176 Federal Street Boston, MA 02110	
Telephone: 617-428-0200 Facsimile: 617-428-7045	
Signature 	Date 